$OBX News
Last published 21h ago
- 21h agoOBXObsidian Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 21h agoOBXObsidian Therapeutics Reports Third Quarter 2026 Financial Results and Business UpdatesBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Obsidian Therapeutics, Inc. (“Obsidian”) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies, today reported financial results for the third quarter ended September 30, 2026, highlighting recent progress and business updates. “2026 has bee ...
- 1mo agoOBXObsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual MeetingBusiness WireObsidian Therapeutics, Inc. ("Obsidian") (NASDAQ:OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell
- 3mo agoOBXObsidian Therapeutics Announces First Patient Enrolled in the Registration-enabling Cohort of Phase 1/2 Agni-01 Study Evaluating Amsoki-cel (OBX-115) in Advanced MelanomaBusiness WireFollowing discussions with FDA, Company has decided to pursue a single-arm trial design intended to support future BLA submission Initiation of registration-enabling cohort follows positive Phase 1/2 results
- 3mo agoOBXObsidian Therapeutics Completes Closing of Transaction with Galera Therapeutics and Previously Announced Private Placement of $350 MillionBusiness WireObsidian Therapeutics to focus on the advancement of its pipeline of novel engineered TIL cell therapies for the treatment of patients with solid tumors Post-transaction cash and cash equivalents of approximately